Fierce Pharma

OCTOBER 28, 2024

Novartis and Apellis Pharmaceuticals have rolled out detailed data on iptacopan and pegcetacoplan, respectively, as they race for the prize in a type of rare kidney disease. Novartis and Apellis dropped new data on their respective meds, iptacopan and pegcetacoplan, in the rare kidney disease C3 glomerulopathy.

Pharmaceutical 313

Pharmaceutical 313

MedCity News

NOVEMBER 26, 2024

While advanced analytics and AI can unlock unprecedented insights, it’s the thoughtful application of these insights that transforms routine interactions between pharmaceutical representatives and healthcare providers into lasting relationships.

Healthcare Provider 298

Healthcare Provider Pharmaceutical Healthcare Healthcare 298

MedCity News

AUGUST 29, 2024

The post In the Pharmaceutical Industry, Ethics are Still More Valuable Than AI appeared first on MedCity News. This responsibility goes beyond mere box-ticking; it requires a deep, introspective examination of our own biases and blind spots and a genuine commitment to putting the well-being of the communities we serve first.

Ethics 278

Ethics Pharmaceutical Biopharma 278

MedCity News

MARCH 31, 2025

Vertex Pharmaceuticals is stopping development of VX-264, an experimental cell therapy/medical device treatment for type 1 diabetes, after an early look at Phase 1/2 data fell short of efficacy goals. This program came from a $950 million acquisition in 2019 that marked Vertexs entry into type 1 diabetes.

Pharmaceutical 264

Pharmaceutical Medical Biopharma Pharma 264

European Pharmaceutical Review

NOVEMBER 21, 2024

The post <em>European Pharmaceutical Review </em> Issue 5 2024 appeared first on European Pharmaceutical Review. Register your details to access this exclusive content!

Pharmaceutical 98

Pharmaceutical Consulting Manufacturing 98

MedCity News

DECEMBER 17, 2024

The Teva Pharmaceuticals and Sanofi drug, duvakitug, showed statistically significant and clinically meaningful results in a Phase 2b study in ulcerative colitis and Crohns disease. The drug is part of an emerging class of therapies that target TL1A, a protein involved in signaling that drives inflammation.

Pharmaceutical 278

Pharmaceutical Biopharma Pharma 278

MedCity News

NOVEMBER 25, 2024

But new competition to both products could come soon from Alnylam Pharmaceuticals, now set to receive an FDA decision in this indication by late March. BridgeBio Pharma claims its drug, Attruby, has an edge over a Pfizer drug as a treatment for cardiomyopathy caused by transthyretin-mediated amyloidosis.

Competition 305

Competition FDA Pharma Pharmaceutical 305

MedCity News

DECEMBER 30, 2024

Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimers agitation drug. One Phase 3 test of Auvelity met its main goal in Alzheimers agitation while the drugs other pivotal trial showed numerical improvement that fell short of statistical significance.

FDA 289

FDA Pharmaceutical products Pharmaceutical Biopharma 289

MedCity News

FEBRUARY 2, 2025

As the pharmaceutical landscape evolves, small-molecule CDMOs will be essential in balancing supply and demand, driving innovation, and improving patient outcomes. They must continue embracing innovation and strategic agility to survive and thrive in this complex environment.

Pharmaceutical 262

Pharmaceutical Patients Biopharma Pharma 262

MedCity News

MAY 16, 2025

BioMarin Pharmaceutical, already well established in enzyme replacement, said it will use its experience and infrastructure to grow the market for this product, potentially for several indications. Inozyme Pharmas main asset is in pivotal testing in children who have a rare enzyme deficiency that affects bones and blood vessels.

Pharma 207

Pharma Pharmaceutical Marketing Biopharma 207

MedCity News

APRIL 7, 2025

Rhythm Pharmaceuticals drug Imcivree met the body mass index reduction goals of a Phase 3 test in hypothalamic obesity, an acquired form of obesity stemming from dysregulation of the MC4R pathway in the hypothalamus. The engineered peptide drug is already approved for two genetically driven types of obesity.

Pharma 241

Pharma Engineering Pharmaceutical FDA 241

MedCity News

FEBRUARY 7, 2025

This business is the pharmaceuticals division of Japanese conglomerate Mitsubishi Chemical Group. Bain Capitals buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease. The post Bain Capital Broadens Its Biotech Reach With $3.3B

Pharma 262

Pharma Pharmaceutical Biopharma 262

MedCity News

NOVEMBER 21, 2024

Ziftomenib is in the same class of medicines as Syndax Pharmaceuticals’ Revuforj, which won FDA approval last week. Kura Oncology already had a broad development plan for ziftomenib in leukemias, but the agreement with Kyowa Kirin provides the cash to execute it and a partner to commercialize the drug globally.

Medicine 277

Medicine FDA Pharmaceutical 277

MedCity News

DECEMBER 23, 2024

Bristol Myers Squibb is trying to add new indications for the drug and stay ahead of competitors including Takeda Pharmaceutical. Sotyktu, which became the first TYK2 inhibitor to reach the market after its 2022 FDA approval in plaque psoriasis, now has positive data from two pivotal tests in psoriatic arthritis.

FDA 277

FDA Pharmaceutical Marketing Biopharma 277

MedCity News

APRIL 17, 2025

The pharmaceutical giant plans global regulatory submissions starting at the end of this year. The first Phase 3 results for Eli Lillys daily pill orforglipron show statistically significant reductions in blood sugar and body weight in patients with type 2 diabetes.

Medicine 235

Medicine Leads Pharmaceutical Patients 235

MedCity News

MAY 14, 2025

GSK is acquiring Boston Pharmaceuticals efimosfermin, which posted Phase 2 results showing improvement in fibrosis and resolution of MASH. GSK said this fusion protein will complement an siRNA drug it is currently developing for liver diseases. The post GSK Makes a Big Liver Disease Move With $1.2B

Pharmaceutical 165

Pharmaceutical Biopharma Pharma 165

MedCity News

FEBRUARY 4, 2025

Supernus Pharmaceuticals Onapgo provides a continuous infusion of apomorphine to manage off periods experienced by Parkinsons disease patients. Approval of Onapgo comes after the FDA twice turned back applications for the drug/device combination product.

FDA 191

FDA Pharmaceutical Management Patients 191

Fierce Pharma

OCTOBER 28, 2024

Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a non-proliferative diabetic retinopathy (NPDR) study, raising doubts about the product’s potential in seve | EyePoint released new diabetic macular edema data Monday that a Mizuho Securities analyst described as "very promising."

Leads 215

Leads Pharmaceutical 215

Contrarian Sales Techniques

MAY 18, 2025

As of May 1, 2025, Malaysia has implemented a significant policy change aimed at enhancing transparency in the pharmaceutical sector. Gathering Market Feedback : Reps can serve as a bridge between healthcare providers and pharmaceutical companies, relaying feedback about pricing concerns, patient responses, and market dynamics.

Pharmaceutical 52

Pharmaceutical Marketing Medical sales Healthcare Provider 52

Pharma Marketing Network

MAY 18, 2025

In the complex world of healthcare, pharmaceutical marketing strategies must evolve to genuinely connect with healthcare professionals (HCPs). Today, digital transformation is central to effective pharmaceutical marketing strategies. FAQs What are pharmaceutical marketing strategies that work best today? How do you get through?

Marketing 52

Marketing Pharmaceutical Education Pharma 52

Fierce Pharma

OCTOBER 17, 2024

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss pharma’s top-selling drug Entresto. | In a court decision filed in Washington, D.C., District Judge Dabney Friedrich rejected Novartis’ position that the FDA’s approval of MSN’s Entresto generic was unlawful.

FDA 249

FDA Pharmaceutical 249

MedCity News

MARCH 23, 2025

But Apellis Pharmaceuticals Empaveli has superior clinical data, and that drug has been submitted for FDA review in the same rare kidney disease as well as another one that does not yet have an approved therapy. Novartiss Fabhalta is the first FDA-approved therapy for C3 glomerulopathy.

FDA 214

FDA Pharma Pharmaceutical Biopharma 214

Fierce Pharma

OCTOBER 11, 2024

Teva Pharmaceuticals USA and Teva Neuroscience have agreed to pay a combined $450 million to resolve claims that the company violated the United States' Anti-Kickback Statute and the False Claims Act, the U.S.

Pharmaceutical 200

Pharmaceutical 200

MedCity News

MARCH 28, 2025

Novo Nordisk gets global rights to Lexicon Pharmaceuticals LX9851, an oral small molecule with a first-in-class approach to sparking weight loss. The licensing agreement comes months after Lexicon reported encouraging preclinical data from tests of LX9851 in combination with semaglutide, the main ingredient in Novo Nordisks Wegovy.

Pharma 179

Pharma Pharmaceutical Biopharma 179

Pharma Marketing Network

MAY 18, 2025

Many marketers in the pharmaceutical industry struggle to balance innovation with regulation, often falling into traps set by outdated beliefs. The post Must Watch Pharmaceutical Trends appeared first on Pharma Marketing Network. This content is not medical advice. For any health issues, always consult a healthcare professional.

Pharmaceutical 52

Pharmaceutical Media Pharma Marketing 52

Fierce Pharma

OCTOBER 22, 2024

billion contract with an unnamed Asia-based pharmaceutical company that’s expected to run through December 2037. With multiple high-profile production pacts already in the books for 2024, CDMO Samsung Biologics has hooked another big one. Following a string of high-profile deals, Samsung Biologics has locked down a $1.2

Pharmaceutical 245

Pharmaceutical 245

Pharma Marketing Network

MAY 9, 2025

Understanding the pharmaceutical market access process is crucialnot only for commercialization teams but for marketers and strategists looking to position their brands competitively. Key Stakeholders and Access Pathways To unlock pharmaceutical market access, its essential to understand the complex web of decision-makers.

Marketing 52

Marketing Pharmaceutical Networking Pharma 52

PharmExec

MAY 14, 2025

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash consideration, including $1.2 billion upfront and up to $800 million in milestone payments.

Pharmaceutical 52

Pharmaceutical 52

Fierce Pharma

DECEMBER 17, 2024

Its the end of an era at Jazz Pharmaceuticals as the drugmakers co-founder and CEO, Bruce Cozadd, eyes his exit after nearly 22 years with the companysome 15 of which were spent at the helm. Current helmsman Bruce Cozadd plans to retire from his role at Jazz Pharmaceuticals in the next 12 months, the company said Monday.

Pharmaceutical 207

Pharmaceutical 207

Fierce Pharma

NOVEMBER 12, 2024

In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval for its liver disease drug Ocaliva has come up short.

FDA 215

FDA Pharmaceutical 215

MedCity News

FEBRUARY 19, 2025

Accepted applicants will be admitted to Altitude Lab, the Salt Lake City biotech accelerator formed by Recursion Pharmaceuticals. Altitude Lab Fund will provide pre-seed funding for early-stage startups affected by changes to grant programs administered by the National Institutes of Health.

Pharma 165

Pharma Pharmaceutical Biopharma 165

MedCity News

AUGUST 6, 2024

The FDA approved Servier Pharmaceuticals’ Voranigo as a treatment for two types of low-grade gliomas. billion acquisition of Agios Pharmaceuticals’ oncology business. The drug, which is projected to become a blockbuster product, comes from Servier’s $1.8

FDA 317

FDA Pharmaceutical Biopharma Pharma 317

MedCity News

APRIL 25, 2024

Regeneron Pharmaceuticals is collaborating with CRISPR technologies startup Mammoth Biosciences to develop in vivo gene-editing therapies. The deal marks the third pharmaceutical industry partnership for Mammoth, which initially focused on developing CRISPR-based diagnostics.

Medicine 336

Medicine Pharmaceutical Biopharma Pharma 336

MedCity News

JULY 22, 2024

Ionis Pharmaceuticals is looking ahead to a Phase 3 study for an antisense medicine it is developing to treat Angelman syndrome, a rare neurodevelopmental disorder with no FDA-approved therapies. Its main competition is an Ultragenyx Pharmaceutical drug set to begin pivotal testing later this year.

Competition 306

Competition Pharmaceutical Medicine FDA 306

MedCity News

JANUARY 22, 2024

In its Phase 3 test, Ionis Pharmaceuticals drug donidalorsen reduced the frequency of swelling attacks caused by the rare disease hereditary angioedema. If Ionis can commercialize this drug, competition would include products from Takeda Pharmaceutical and BioCryst Pharmaceuticals.

Competition 296

Competition Pharmaceutical FDA Biopharma 296

MedCity News

MARCH 25, 2025

Apellis Pharmaceuticals and Astellas Pharma have the first two FDA-approved therapies for geographic atrophy, but Character Biosciences claims its approach could be best in class for treating this advanced form of dry age-related macular degeneration.

Pharma 179

Pharma FDA Pharmaceutical Biopharma 179

MedCity News

JULY 18, 2024

Expanded FDA approval of Phathom Pharmaceuticals drug Voquezna now includes patients with non-erosive gastroesophageal reflux disease (GERD). Phathom licensed its flagship product from Takeda Pharmaceutical. The post Heartburn Drug from Phathom Pharma Expands Its Approval to Cover More GERD Patients appeared first on MedCity News.

Pharma 278

Pharma Patients FDA Pharmaceutical 278